Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs

Atopic dermatitis (AD) represents the most common skin disease characterized by heterogeneous endophenotypes and a high disease burden. In Europe, six new systemic therapies for AD have been approved: the biologics dupilumab (anti‐interleukin‐4 receptor (IL‐4R) α in 2017), tralokinumab (anti‐IL‐13 i...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Allergy (Copenhagen) Ročník 79; číslo 6; s. 1501 - 1515
Hlavní autori:	Müller, Svenja, Maintz, Laura, Bieber, Thomas
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Denmark Blackwell Publishing Ltd 01.06.2024
Predmet:	Atopic dermatitis biological therapy Cardiovascular diseases Clinical trials Dermatitis Drug development drug therapy Inhibitor drugs Janus kinase Malignancy Mesenchymal stem cells Monoclonal antibodies Neurokinin Opioid receptors Ox40L protein Precision medicine Skin diseases Thromboembolism Transient receptor potential proteins Tumor necrosis factor drug development atopic dermatitis precision medicine drug therapy biological therapy
ISSN:	0105-4538, 1398-9995, 1398-9995
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!